Cure Parkinson’s is an international funder of both preclinical and clinical research. Here we discuss the types of preclinical research we support.

Before an experimental therapy can be tested in humans, there needs to be evidence that it works in models of Parkinson’s. This data helps provide a case for support in taking the treatment forward into clinical testing.

In addition to our extensive clinical trial programme, Cure Parkinson’s also funds preclinical research which provides the data that justifies the need to clinically test a particular therapy.

When I joined the organisation, one of the aspects of Cure Parkinson’s that I really liked was the focused nature of the research funding – we are only interested in a cure for Parkinson’s

Dr Simon Stott – Deputy Director of Research

Cure Parkinson’s is selective, however, in the nature of the preclinical research we fund. The studies we support must be focussed on changing the course of Parkinson’s (disease modifying) and must be within 5 years of reaching the clinic.

As a result of this very specific funding remit, we focus our resources on experimental therapies that have the potential to help cure this condition. We do not fund research exploring the basic biology of Parkinson’s. Nor do we fund studies evaluating symptomatic therapies (treatments that temporarily cover up the symptoms of Parkinson’s).

Preclinical research that was previously supported by Cure Parkinson’s included screening clinically approved drugs that inhibit particular Parkinson’s-associated proteins. We have also funded studies investigating novel agents (that are being clinically developed for other medical conditions) in models of Parkinson’s to determine if they should be repurposed for Parkinson’s.